1. Home
  2. CABA vs NIU Comparison

CABA vs NIU Comparison

Compare CABA & NIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CABA
  • NIU
  • Stock Information
  • Founded
  • CABA 2017
  • NIU 2014
  • Country
  • CABA United States
  • NIU China
  • Employees
  • CABA N/A
  • NIU N/A
  • Industry
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • NIU Auto Manufacturing
  • Sector
  • CABA Health Care
  • NIU Consumer Discretionary
  • Exchange
  • CABA Nasdaq
  • NIU Nasdaq
  • Market Cap
  • CABA 233.2M
  • NIU 275.6M
  • IPO Year
  • CABA 2019
  • NIU 2018
  • Fundamental
  • Price
  • CABA $2.32
  • NIU $3.86
  • Analyst Decision
  • CABA Strong Buy
  • NIU
  • Analyst Count
  • CABA 8
  • NIU 0
  • Target Price
  • CABA $13.50
  • NIU N/A
  • AVG Volume (30 Days)
  • CABA 5.3M
  • NIU 405.5K
  • Earning Date
  • CABA 11-10-2025
  • NIU 11-17-2025
  • Dividend Yield
  • CABA N/A
  • NIU N/A
  • EPS Growth
  • CABA N/A
  • NIU N/A
  • EPS
  • CABA N/A
  • NIU N/A
  • Revenue
  • CABA N/A
  • NIU $527,760,629.00
  • Revenue This Year
  • CABA N/A
  • NIU $42.51
  • Revenue Next Year
  • CABA N/A
  • NIU $23.71
  • P/E Ratio
  • CABA N/A
  • NIU N/A
  • Revenue Growth
  • CABA N/A
  • NIU 32.62
  • 52 Week Low
  • CABA $0.99
  • NIU $1.66
  • 52 Week High
  • CABA $5.46
  • NIU $5.67
  • Technical
  • Relative Strength Index (RSI)
  • CABA 44.66
  • NIU 39.00
  • Support Level
  • CABA $2.30
  • NIU $3.73
  • Resistance Level
  • CABA $2.67
  • NIU $4.29
  • Average True Range (ATR)
  • CABA 0.33
  • NIU 0.17
  • MACD
  • CABA -0.07
  • NIU -0.01
  • Stochastic Oscillator
  • CABA 8.05
  • NIU 20.29

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

About NIU Niu Technologies

Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.

Share on Social Networks: